Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 Clinical Study of DTX401 Gene Therapy in Glycogen ...
DTX401 Response Observed in All Three Patients, with Two Patients Demonstrating Clinically Meaningful Improvement in Time to Hypoglycemia Study to Advance to Cohort 2 at a Higher Dose NOVATO, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Ultragenyx …